antiviral

Vins Bio Products Limited - Vins Research Wins Life.

Anti Rabies Serum (Vinrab – 1000 I.U) 5mL Liquid

VINS – VINRAB 1000 IU (5 ml vial)

Composition:

Each vial contains:

  • Equine anti rabies immunoglobulin fragments – not less than 200 I.U./ml.
  • Cresol I.P. < 0.25% v/v as a preservative.
  • Glycine I.P. – 0.0225 g/ml
  • Sodium Chloride I.P. – 0.009 g/ml
  • Water for injection I.P. – q.s.

Description:

Rabies antiserum is a sterile, non-pyrogenic solution for intra-muscular administration, containing antiviral substances obtained from the blood serum of healthy equines that have been immunized against rabies by vaccination. In addition, it also contains the anti-microbial agent cresol.

Therapeutic Indications:

Rabies antiserum provides passive immunization against rabies for prevention of rabies in patients at risk of being exposed to rabies after contact with a rabid animal or an animal presumed to be rabid. Anti-rabies serum itself does not constitute an anti-rabies treatment and should always be used in conjunction with rabies vaccine.

Contra-Indications:

Should be used with extreme caution in subjects with a history of allergic symptoms or hypersensitivity to equine serum.

Despite the high degree of purification of the serum, it is recommended to perform a skin test before administering Rabies antiserum. The skin test consists of an intra-dermal injection with a 1:10 dilution of Rabies antiserum (0.1 ml) on the outside of the forearm so as to obtain an orange ring type appearance (3 mm diameter induration). An equivalent intra-dermal injection of physiological saline solution is used as control. The observations made 15 minutes after intra-dermal injection is considered to be positive if erythema (>6 mm), local oedema or a systemic reaction is observed and the control shows no such dermal reaction. Purified equine rabies immunoglobulin (the active constituent of rabies immunoserum) has been reported to be safe and affordable alternative to human rabies immunoglobulin. (Bulletin WHO 1989, 67(731-732). A positive test result is not a formal contra-indication for the use of sero-therapy, but it should be considered as a warning. In such cases Rabies antiserum should be administered only after ensuring the facility to overcome the anaphylactic shock. A negative test is not an absolute guarantee for the absence of an immediate allergic type reaction.

Rabies prevention after contamination risk requires simultaneous administration of anti-rabies immunoglobulin and vaccine to be inoculated in different parts of the body, contra-laterally if possible. To minimize interference, the antiserum should not be administered from the same syringe as the vaccine.

The safety of rabies immunoserum when used during pregnancy has not been established in clinical trials in human beings. Considering the lethal risk associated with rabies, pregnancy may not a contraindication to the administration of rabies immunoserum subsequent to exposure.

Dosage and Administration

Prompt local treatment of bite wounds and scratches that may be contaminated with rabies virus is important, whatever the time elapsed since the contact. Recommended first-aid procedures are imminent thorough flushing and washing of the wound with soap and water, detergent or other substance of proven lethal effect on rabies virus. The rabies immunoserum should be injected as soon as possible after exposure.

Category Type of contact with a suspect or confirmed rabid domestic or wild animal or animal not available for observation Recommended Treatment
1 Touching or feeding, licks on intact skin None, if reliable case history is available
2 Nibbling of uncovered skin. Minor scratches or abrasions without bleeding. Licks on broken skin. Administer vaccine immediately. Stop treatment if animal remains healthy throughout the observation period of 10 days or if the animal is killed humanely and found to be negative for rabies by appropriate laboratory techniques. Administer Antirabies serum (ARS) along with Anti rabies vaccine (ARV) to immuno-compromised patients.
3 Single or multiple transdermal bites or scratches. Contamination of mucous membrane with saliva (i.e. licks) Administer rabies immunoserum and rabies vaccine immediately. Stop treatment if animal remains healthy throughout the observation period of 10 days or the animal is killed humanely and found to be negative for rabies by appropriate laboratory techniques.

 

For prevention of rabies combined immunoglobulin-vaccine treatment is recommended. The recommended dose is 40 I.U./KG of body weight. If anatomically feasible, as much as possible of the dose should be infiltrated around the wounds. The remainder should be administered intramuscularly (into the gluteal region) in a single dose. The first dose of the vaccine should be inoculated at the same time as the immunoglobulin, but in different parts of the body. Children and adults receive the same dose of 40 I.U. /Kg of body weight. When indicated, begin anti-tetanus treatment and administer anti-microbial drugs to control infections other than rabies.

Immediate or delayed hypersensitive type reactions may be developed on administration of rabies immunoserum. The observed immediate reactions are anaphylactoid reactions with hypotension, dyspnoea, and urticaria. Delayed reactions consist of inflammatory reaction, fever, pruritis, rash or urticaria, adenopathy and arthralgia.

Store at a temperature between +20C and +80C in a refrigerator, DO NOT FREEZE.

Vials containing 1000 I.U. (5 ml).

Anti Rabies Serum (Vinrig - 1500 I.U) 5 ml Liquid

VINS – VINRIG I.P.1500 IU (5 ml vial)

Composition:

Each vial contains:

  • Equine anti-rabies immunoglobulin fragments – not less than 300 I.U./ml.
  • Cresol I.P. < 0.25% v/v as a preservative.
  • Glycine I.P. – 0.0225 g/ml
  • Sodium Chloride I.P. – 0.009 g/ml
  • Water for injection I.P. – q.s.

Description:

Rabies antiserum is a sterile, nonpyrogenic solution for intramuscular administration, containing antiviral substances obtained from the blood serum of healthy equines that have been immunized against rabies by vaccination. In addition, it also contains the antimicrobial agent cresol.

Therapeutic Indications:

Rabies antiserum provides passive immunization against rabies for prevention of rabies in patients at risk of being exposed to rabies after contact with a rabid animal or an animal presumed to be rabid. Anti-rabies serum itself does not constitute an anti-rabies treatment and should always be used in conjunction with rabies vaccine.

Contra-Indications:

Should be used with extreme caution in subjects with a history of allergic symptoms or hypersensitivity to equine serum.

Despite the high degree of purification of the serum, it is recommended to perform a skin test before administering Rabies antiserum. The skin test consists of an intradermal injection with a 1:10 dilution of Rabies antiserum (0.1 ml) on the outside of the forearm so as to obtain an orange ring type appearance (3 mm diameter induration). An equivalent intradermal injection of physiological saline solution is used as control. The observations made 15 minutes after intradermal injection is considered to be positive if erythema (>6 mm), local oedema or a systemic reaction is observed and the control shows no such dermal reaction. Purified equine rabies immunoglobulin (the active constituent of rabies immunoserum) has been reported to be safe and affordable alternative to human rabies immunoglobulin. (Bulletin WHO 1989, 67(731-732). A positive test result is not a formal contra-indication for the use of serotherapy, but it should be considered as a warning. In such cases Rabies antiserum should be administered only after ensuring the facility to overcome the anaphylactic shock. A negative test is not an absolute guarantee for the absence of an immediate allergic type reaction.

Rabies prevention after contamination risk requires simultaneous administration of anti-rabies immunoglobulin and vaccine to be inoculated in different parts of the body, contra-laterally if possible. To minimize interference, the antiserum should not be administered from the same syringe as the vaccine.

The safety of rabies immunoserum when used during pregnancy has not been established in clinical trials in human beings. Considering the lethal risk associated with rabies, pregnancy may not a contraindication to the administration of rabies immunoserum subsequent to exposure.

Prompt local treatment of bite wounds and scratches that may be contaminated with rabies virus is important, whatever the time elapsed since the contact. Recommended first-aid procedures are imminent thorough flushing and washing of the wound with soap and water, detergent or other substance of proven lethal effect on rabies virus. The rabies immunoserum should be injected as soon as possible after exposure.

Category Type of contact with a suspect or confirmed rabid domestic or wild animal or animal not available for observation Recommended Treatment
1 Touching or feeding, licks on intact skin None, if reliable case history is available
2 Nibbling of uncovered skin. Minor scratches or abrasions without bleeding. Licks on broken skin. Administer vaccine immediately. Stop treatment if animal remains healthy throughout the observation period of 10 days or if the animal is killed humanely and found to be negative for rabies by appropriate laboratory techniques. Administer Antirabies serum (ARS) along with Anti rabies vaccine (ARV) to immuno-compromised patients.
3 Single or multiple transdermal bites or scratches. Contamination of mucous membrane with saliva (i.e. licks) Administer rabies immunoserum and rabies vaccine immediately. Stop treatment if animal remains healthy throughout the observation period of 10 days or the animal is killed humanely and found to be negative for rabies by appropriate laboratory techniques.

For prevention of rabies combined immunoglobulin vaccine treatment is recommended. The recommended dose is 40 I.U./KG of body weight. If anatomically feasible, as much as possible of the dose should be infiltrated around the wounds. The remainder should be administered intramuscularly (into the gluteal region) in a single dose. The first dose of the vaccine should be inoculated at the same time as the immunoglobulin, but in different parts of the body. Children and adults receive the same dose of 40 I.U. /Kg of body weight. When indicated, begin anti-tetanus treatment and administer antimicrobial drugs to control infections other than rabies.

Immediate or delayed hypersensitive type reactions may be developed on administration of rabies immunoserum. The observed immediate reactions are anaphylactoid reactions with hypotension, dyspnoea, and urticaria. Delayed reactions consist of inflammatory reaction, fever, pruritis, rash or urticaria, adenopathy and arthralgia.

Store at a temperature between +20C and +80C in a refrigerator, DO NOT FREEZE.

Vials containing 1500 I.U. (5 ml).